- Home
- LLYVK vs ALKS Comparison
LLYVK vs ALKS Comparison
Compare LLYVK & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVK
- ALKS
- Stock Information
- Founded
- LLYVK 1991
- ALKS 1987
- Country
- LLYVK United States
- ALKS Ireland
- Employees
- LLYVK N/A
- ALKS N/A
- Industry
- LLYVK Broadcasting
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- LLYVK Industrials
- ALKS Health Care
- Exchange
- LLYVK Nasdaq
- ALKS Nasdaq
- Market Cap
- LLYVK 6.7B
- ALKS 4.5B
- IPO Year
- LLYVK N/A
- ALKS 1991
- Fundamental
- Price
- LLYVK $74.61
- ALKS $30.38
- Analyst Decision
- LLYVK
- ALKS Buy
- Analyst Count
- LLYVK 0
- ALKS 12
- Target Price
- LLYVK N/A
- ALKS $38.33
- AVG Volume (30 Days)
- LLYVK 313.3K
- ALKS 1.9M
- Earning Date
- LLYVK 01-01-0001
- ALKS 05-01-2025
- Dividend Yield
- LLYVK N/A
- ALKS N/A
- EPS Growth
- LLYVK N/A
- ALKS N/A
- EPS
- LLYVK N/A
- ALKS 2.09
- Revenue
- LLYVK N/A
- ALKS $1,513,770,000.00
- Revenue This Year
- LLYVK $7.29
- ALKS N/A
- Revenue Next Year
- LLYVK N/A
- ALKS $4.09
- P/E Ratio
- LLYVK N/A
- ALKS $14.59
- Revenue Growth
- LLYVK N/A
- ALKS N/A
- 52 Week Low
- LLYVK $33.50
- ALKS $22.90
- 52 Week High
- LLYVK $81.66
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- LLYVK 61.08
- ALKS 53.77
- Support Level
- LLYVK $69.60
- ALKS $26.70
- Resistance Level
- LLYVK $75.53
- ALKS $31.99
- Average True Range (ATR)
- LLYVK 2.09
- ALKS 1.06
- MACD
- LLYVK 0.48
- ALKS 0.50
- Stochastic Oscillator
- LLYVK 89.55
- ALKS 69.57
About LLYVK Liberty Media Corporation
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.